Delcath Systems Inc
DCTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$522.31M
Close$
$1.07
93% downside
Current Fair Value
93% downsideOvervalued by 93% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $522.31 Million |
|---|---|
| Enterprise Value | $477.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.08 |
| Beta | 0.57 |
| Outstanding Shares | 35,891,915 |
Return
| Return on Equity | 0.44% |
|---|---|
| Return on Assets | 0.39% |
| Return on Invested Capital | 0.45% |
Valuation & Multiples
| P/E Ratio | 1375.45 |
|---|---|
| PEG | -127917.27 |
| Price to Sales | 15.13 |
| Price to Book Ratio | 5.04 |
| Enterprise Value to Revenue | 9.6 |
| Enterprise Value to EBIT | 847.7 |
| Enterprise Value to Net Income | 897 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$26.25 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$26.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5806▼ 29.50% |
|---|---|
| Total Calls | 312,800▲ 14.49% |
| Total Puts | 181,600▼ 24.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 48.60%▲ 3.30% |
|---|---|
| Total Invested | $220.32M▲ 45.40% |
| Investors Holding | 1290% |
ESG Score
No data
About Delcath Systems Inc
CEO: Jennifer Simpson Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...